Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Ovid Technologies (Wolters Kluwer Health) ; 1997
    In:  The Pediatric Infectious Disease Journal Vol. 16, No. 3 ( 1997-03), p. 293-297
    In: The Pediatric Infectious Disease Journal, Ovid Technologies (Wolters Kluwer Health), Vol. 16, No. 3 ( 1997-03), p. 293-297
    Type of Medium: Online Resource
    ISSN: 0891-3668
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 1997
    detail.hit.zdb_id: 2020216-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Ovid Technologies (Wolters Kluwer Health) ; 1998
    In:  The Pediatric Infectious Disease Journal Vol. 17, No. 11 ( 1998-11), p. 1049-1050
    In: The Pediatric Infectious Disease Journal, Ovid Technologies (Wolters Kluwer Health), Vol. 17, No. 11 ( 1998-11), p. 1049-1050
    Type of Medium: Online Resource
    ISSN: 0891-3668
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 1998
    detail.hit.zdb_id: 2020216-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: JCO Global Oncology, American Society of Clinical Oncology (ASCO), , No. 8 ( 2022-08)
    Abstract: Waldenstrom Macroglobulinemia (WM) is a rare lymphoma with distinct clinical features, and data from Latin American patients are lacking. Therefore, we aim to investigate the clinical, therapy, and outcome patterns of WM in Latin America. METHODS We retrospectively analyzed patients with WM diagnosed between 1991 and 2019 from 24 centers in seven Latin American countries. The study outcomes were overall survival (OS) and progression-free survival (PFS). RESULTS We identified 159 cases (median age 67 years, male 62%). Most patients (95%) were symptomatic at diagnosis. The International Prognostic Scoring System for WM (IPSSWM) at diagnosis was available in 141 (89%) patients (high-risk 40%, intermediate-risk 37%, and low-risk 23%). Twenty-seven (17%) patients were tested for MYD88 L265P , with 89% (n = 24 of 27) carrying the mutation. First-line and second-line therapies were administered to 142 (89%) and 53 (33%) patients, respectively. Chemoimmunotherapy was the most commonly used first-line (66%) and second-line (45%) approach; only 18 (11%) patients received ibrutinib. With a median follow-up of 69 months, the 5-year OS rate was 81%. In treated patients, the 5-year OS and PFS rates were 78% and 59%, respectively. High-risk IPSSWM at treatment initiation was an independent risk factor for OS (adjusted hazard ratio: 4.73, 95% CI, 1.67 to 13.41, P = .003) and PFS (adjusted hazard ratio: 2.43, 95% CI, 1.31 to 4.50, P = .005). CONCLUSION In Latin America, the management of WM is heterogeneous, with limited access to molecular testing and novel agents. However, outcomes were similar to those reported internationally. We validated the IPSSWM score as a prognostic factor for OS and PFS. There is an unmet need to improve access to recommended diagnostic approaches and therapies in Latin America.
    Type of Medium: Online Resource
    ISSN: 2687-8941
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2022
    detail.hit.zdb_id: 3018917-2
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 31, No. 8 ( 2022-08-02), p. 1602-1609
    Abstract: Breast cancer incidence in the United States is lower in Hispanic/Latina (H/L) compared with African American/Black or Non-Hispanic White women. An Indigenous American breast cancer–protective germline variant (rs140068132) has been reported near the estrogen receptor 1 gene. This study tests the association of rs140068132 and other polymorphisms in the 6q25 region with subtype-specific breast cancer risk in H/Ls of high Indigenous American ancestry. Methods: Genotypes were obtained for 5,094 Peruvian women with (1,755) and without (3,337) breast cancer. Associations between genotype and overall and subtype-specific risk for the protective variant were tested using logistic regression models and conditional analyses, including other risk-associated polymorphisms in the region. Results: We replicated the reported association between rs140068132 and breast cancer risk overall [odds ratio (OR), 0.53; 95% confidence interval (CI), 0.47–0.59], as well as the lower odds of developing hormone receptor negative (HR−) versus HR+ disease (OR, 0.77; 95% CI, 0.61–0.97). Models, including HER2, showed further heterogeneity with reduced odds for HR+HER2+ (OR, 0.68; 95% CI, 0.51–0.92), HR−HER2+ (OR, 0.63; 95% CI, 0.44–0.90) and HR−HER2− (OR, 0.77; 95% CI, 0.56–1.05) compared with HR+HER2−. Inclusion of other risk-associated variants did not change these observations. Conclusions: The rs140068132 polymorphism is associated with decreased risk of breast cancer in Peruvians and is more protective against HR− and HER2+ diseases independently of other breast cancer-associated variants in the 6q25 region. Impact: These results could inform functional analyses to understand the mechanism by which rs140068132-G reduces risk of breast cancer development in a subtype-specific manner. They also illustrate the importance of including diverse individuals in genetic studies.
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 32, No. 1_Supplement ( 2023-01-01), p. C082-C082
    Abstract: Breast cancer subtype distribution differs between populations with dissimilar genetic ancestry backgrounds. Several breast cancer risk single nucleotide polymorphisms (SNPs) were discovered in individuals of European and Asian origin. Hispanic/Latina women remain underrepresented in studies and public databases. The 6q25 locus contains multiple breast cancer risk-associated SNPs. Some SNPs within this region have been associated with the expression of genes (eQTLs), such as the Estrogen Receptor 1 gene (ESR1). Two breast cancer genetic association studies in Hispanics/Latinas identified two SNPs (rs140068132 and rs3778609), near ESR1, that correlate with Indigenous American ancestry and reduce the odds of breast cancer, especially for Estrogen Receptor-negative (ER-) disease. The underrepresentation of Latin American populations in public databases has hindered the study of the mechanisms by which these SNPs confer a protective effect. We integrated genetic and transcriptomic data from breast cancer patients with high Indigenous American ancestry to test the association between the protective variants in the 6q25 region and tumor gene expression. Breast cancer patients were recruited at the National Cancer Institute in Peru to be part of The Peruvian Genetics and Genomics of Breast Cancer Study (PEGEN-BC, N=1809). Healthy women from a pregnancy outcomes study in Peru were included as controls (N=3334). Genome-wide genotype data were available and missing genotypes were imputed using the TOPMED Imputation Server to perform fine-mapping within the 6q25 locus. Logistic regression was used to test the association between each SNP and breast cancer risk. We exome-sequenced 155 breast tumors of these patients. Transcripts per million counts and imputed genotypes within the 6q25 region were used for eQTL analysis. Colocalization was performed using summary statistics from the fine-mapping and eQTL analysis, including SNPs with minor allele frequency & gt;5%. Only two SNPs, rs140068132 and rs851984 were independently associated with breast cancer risk, as we previously reported. eQTL signals colocalized with the subregion in 6q25 that contains these breast cancer-associated SNPs. Within this subregion, the gene with more eQTLs using a nominal p-value of & lt;=0.01 was MTHFD1L (136 eQTLs), followed by ESR1 (58) and CCDC170 (32). Colocalization showed that MTHFD1L and ESR1 eQTLs were more likely to overlap with breast cancer risk SNPs, including rs140068132. The protective rs140068132-G variant was associated with lower expression of MTHFD1L. MTHFD1L has been found deregulated in breast cancer and higher expression is associated with poor prognosis. Our preliminary results suggest that the rs140068132-G variant in the 6q25 region identified in Hispanic/Latina women might exert its protective effect through the downregulation of MTHFD1L. Analyses with additional samples will allow us to confirm this result and further explore the functional implications of the rs140068132 variant. Citation Format: Valentina A. Zavala, Xiaosong Huang, Sandro Casavilca-Zambrano, Jeannie Navarro-Vásquez, Carlos A. Castañeda, Guillermo Valencia, Zaida Morante, Monica Calderon, Julio E. Abugattas, Henry Gómez, Hugo A. Fuentes, Ruddy Liendo-Picoaga, Jose M. Cotrina, Silvia Neciosup, Katia Roque, Jule Vásquez, Luis MAs, Marco Gálvez-Nino, Sixto E. Sánchez, Michelle A. Williams, Elad Ziv, Jovanny Zabaleta, Bizu Gelaye, Tatiana Vidaurre Vidaurre, Laura Fejerman. Breast cancer risk in Hispanic/Latina women and the 6q25 chromosomal region: Fine mapping and eQTL identification [abstract]. In: Proceedings of the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2022 Sep 16-19; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr C082.
    Type of Medium: Online Resource
    ISSN: 1538-7755
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 83, No. 7_Supplement ( 2023-04-04), p. 5235-5235
    Abstract: Purpose: Breast cancer incidence and outcomes differ by US census racial/ethnic category. Since large-scale genetic studies of human disease are predominately focused on populations of European ancestry, little is known about breast cancer molecular biology in Hispanic/Latinos which can widen cancer health disparities due to suboptimal translation of discoveries into clinical practice or public health policy. We aim to describe relevant pathways in breast cancer subtype differentiation in breast cancer patients from Peru. Patients and Methods: Formalin fixed paraffin embedded tumor tissues samples were whole exome sequenced for a total of 271 patients, recruited by the Peruvian Breast Cancer Genomics Study (PEGEN-BC) from the Instituto Nacional de Enfermedades Neoplásicas (INEN) in Lima, Peru. Quality control was conducted to remove genes with low counts. Intrinsic tumor subtypes were classified using the PAM50 method using genefu package in R. Differential gene expression between subtypes was performed by DEseq2 R package and statistical significance was determined using FDR & lt;0.05 for samples with at least log2 1.5-fold change. Pathway analyses were performed to explore differences among the subtypes using GSEA with fgsea package in R. Indigenous American ancestry proportions for participants were estimated using germline genome-wide genotypes and the program Admixture. Results: The mean age of patients was 50 and the median Indigenous American ancestry was 79%. PAM50 classification of the sequenced samples defined 20.2% of tumors as LumA, 27.9% as LumB, 27.1% as HER2, 22.5% as Basal and 2.3% as Normal. Transcriptomic pathway analysis showed that most of the significantly changed pathways were similar to those previously described such as upregulation of high proliferation pathways in LumB, HER2E and Basal tumors, and a strong dependency on the estrogen pathway for LumA. Top 10 significantly changed pathways show some unique findings: the epithelial-mesenchymal-transition (EMT) pathway is downregulated in Basal, comparing to LumA and HER2 tumors, which is unexpected given that the EMT is associated with stem cell features and poor outcomes. The E2F-targets pathway is upregulated in LumA when comparing to HER2 tumors, but downregulated when compared to Basal tumors. Conclusions: We identified novel pathways associated with breast cancer subtypes in individuals with high Indigenous American ancestry from Peru and are working on testing the robustness of these findings. If our findings are confirmed, results would suggest a more aggressive profile of Luminal subtypes in the studied samples from Peru, with implications for treatment and survival. Citation Format: Chenghuiyun Xu, Valentina A. Zavala-Cordero, Xiaosong Huang, David M. Rocke, Sandro Casavilca-Zambrano, Jeannie M. Navarro-Vásquez, Carlos A. Castañeda, Guillermo Valencia, Zaida Morante, Monica Calderón, Julio E. Abugattas, Henry Gómez, Hugo A. Fuentes, Ruddy Liendo-Picoaga, Jose M. Cotrina, Silvia P. Neciosup, Katia Roque, Jule Vásquez, Luis Mas, Marco Gálvez-Nino, Jovanny Zabaleta, Tatiana Vidaurre, Laura Fejerman. Transcriptome-wide study of tumor samples from Peruvian women identifies dysregulated pathways in luminal tumors typically associated with more aggressive disease. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5235.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    JSTOR ; 1983
    In:  Radiation Research Vol. 94, No. 3 ( 1983-06), p. 513-
    In: Radiation Research, JSTOR, Vol. 94, No. 3 ( 1983-06), p. 513-
    Type of Medium: Online Resource
    ISSN: 0033-7587
    RVK:
    Language: Unknown
    Publisher: JSTOR
    Publication Date: 1983
    detail.hit.zdb_id: 2135113-2
    detail.hit.zdb_id: 80322-4
    SSG: 11
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    In: Frontiers in Oncology, Frontiers Media SA, Vol. 13 ( 2023-2-16)
    Abstract: Breast cancer is a heterogeneous disease, and the distribution of the different subtypes varies by race/ethnic category in the United States and by country. Established breast cancer-associated factors impact subtype-specific risk; however, these included limited or no representation of Latin American diversity. To address this gap in knowledge, we report a description of demographic, reproductive, and lifestyle breast cancer-associated factors by age at diagnosis and disease subtype for The Peruvian Genetics and Genomics of Breast Cancer (PEGEN-BC) study. Methods The PEGEN-BC study is a hospital-based breast cancer cohort that includes 1943 patients diagnosed at the Instituto Nacional de Enfermedades Neoplásicas in Lima, Peru. Demographic and reproductive information, as well as lifestyle exposures, were collected with a questionnaire. Clinical data, including tumor Hormone Receptor (HR) status and Human Epidermal Growth Factor Receptor 2 (HER2) status, were abstracted from electronic medical records. Differences in proportions and mean values were tested using Chi-squared and one-way ANOVA tests, respectively. Multinomial logistic regression models were used for multivariate association analyses. Results The distribution of subtypes was 52% HR+HER2-, 19% HR+HER2+, 16% HR-HER2-, and 13% HR-HER2+. Indigenous American (IA) genetic ancestry was higher, and height was lower among individuals with the HR-HER2+ subtype (80% IA vs. 76% overall, p =0.007; 152 cm vs. 153 cm overall, p =0.032, respectively). In multivariate models, IA ancestry was associated with HR-HER2+ subtype (OR=1.38,95%CI=1.06-1.79, p =0.017) and parous women showed increased risk for HR-HER2+ (OR=2.7,95%CI=1.5-4.8, p & lt;0.001) and HR-HER2- tumors (OR=2.4,95%CI=1.5-4.0, p & lt;0.001) compared to nulliparous women. Multiple patient and tumor characteristics differed by age at diagnosis ( & lt;50 vs. & gt;=50), including ancestry, region of residence, family history, height, BMI, breastfeeding, parity, and stage at diagnosis ( p & lt;0.02 for all variables). Discussion The characteristics of the PEGEN-BC study participants do not suggest heterogeneity by tumor subtype except for IA genetic ancestry proportion, which has been previously reported. Differences by age at diagnosis were apparent and concordant with what is known about pre- and post-menopausal-specific disease risk factors. Additional studies in Peru should be developed to further understand the main contributors to the specific age of onset and molecular disease subtypes in this population and develop population-appropriate predictive models for prevention.
    Type of Medium: Online Resource
    ISSN: 2234-943X
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2023
    detail.hit.zdb_id: 2649216-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 83, No. 7_Supplement ( 2023-04-04), p. 5237-5237
    Abstract: Genetic studies in women of Hispanic/Latina origin identified a single nucleotide polymorphism (SNP) in the 6q25 region, rs140068132, that correlates with Indigenous American (IA) ancestry and is protective against BC. The underrepresentation of Latin American populations in public databases has hindered the study of the mechanisms by which this SNP confers a protective effect. We aimed to identify IA germline variants associated with BC risk and to test their association with tumor gene expression in this region. We performed a case-control fine-mapping analysis in the 6q25 region. BC patients part of the PEGEN-BC Study (N=1809) were included as cases and women from a pregnancy outcomes study in Peru as controls (N=3334). Genome-wide genotype data were available and missing genotypes were imputed using the TOPMED Imputation Server. Logistic regression was used to test the association between each SNP and BC risk. We exome-sequenced 247 breast tumors of PEGEN-BC patients. Tumor subtype was assigned by the pam50 method. We excluded patients diagnosed with stage IV disease, with tumors classified as normal-like or as uncertain, and carriers of the GG genotype for rs140068132, leaving 242 samples. Association between rs140068132 and gene expression of genes in the 6q25 region was tested adjusting by age at diagnosis and IA ancestry. The strongest signal corresponded to rs140068132 (odds ratio (OR)=0.53, p=1.9e-21). The model adjusted by rs140068132 revealed three additional independent variants that correlate with Indigenous American ancestry: rs184135739 (OR=0.8, p=0.006), rs141057867 (OR=0.87, p=0.006) and rs140125124 (OR=1.23, p=0.015). Gene expression analysis stratified by subtype revealed that among HER2+ tumors (N=63), rs140068132 was associated with ARMT1 (fold change comparing AA to AG (FC)=1.6, p & lt;0.01), CCDC170 (FC=1.8, p & lt;0.01), MTHFD1L (FC=0.7, p & lt;0.01) and RMND1 (FC=1.4, p=0.013). Among Luminal-B (N=68) tumors, there was an association with ARMT1 (FC= 1.9, p=0.001), ESR1 (FC=1.4, p=0.04) and MTHFD1L (FC= 0.8, p=0.02). Only ESR1 was associated with the SNP (FC= 0.5, p= 0.03) among basal tumors (N=56). No association was identified among Luminal-A tumors (N=55). rs141057867 showed evidence of cis-association with CLDN20 (FC=1.4, p=0.014) among HER2+ subtypes and rs184135739 with ZC3H12D (FC=2.1, p=0.02) and SUMO4 (FC=1.8, p=0.023) among Lumina-A tumors. Two of the three novel IA SNPs are protective against BC and show association with gene expression. The rs140068132-G variant regulates the expression of genes in the 6q25 region in a subtype-specific manner. A possible mechanism explaining the protective effect of the rs140068132 polymorphism might be linked to the lower expression of MTHFD1L among G-allele carriers in some subtypes. This gene is deregulated in cancer and its expression is negatively associated with cancer survival, including BC. Citation Format: Valentina A. Zavala, Xiaosong Huang, Sandro Casavilca-Zambrano, Jeannie Navarro-Vásquez, Carlos A. Castañeda, Guillermo Valencia, Zaida Morante, Monica Calderon, Julio E. Abugattas, Henry Gómez, Hugo Fuentes, Ruddy Liendo-Picoaga, Jose M. Cotrina, Katia Roque, Jule Vásquez, Luis Mas, Marco Gálvez-Nino, Jovanny Zabaleta, Tatiana Vidaurre, Laura Fejerman. Regulation of genes located in 6q25 by an Indigenous American genetic variant in breast cancer patients from Peru. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5237.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages